|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"lu li chun"
Showing items 6-30 of 38 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2022-02-21T06:00:15Z |
Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites
|
Guo, Jhe-Cyuan; Lin, Chen-Yuan; Lin, Chia-Chi; Huang, Ta-Chen; Lien, Ming-Yu; Lu, Li-Chun; HUNG-YANG KUO; CHIH-HUNG HSU |
| 臺大學術典藏 |
2022-01-12T08:28:38Z |
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang, Yu-Wen; Tsai, Xavier Cheng-Hong; Hou, Hsin-An; TIEN FENG-MING; LIU JIA-HAU; Chou, Wen-Chien; Ko, Bor-Sheng; Chen, Yu-Wen; Lin, Chien-Chin; Chieh-Lung Cheng; Lo, Min-Yen; LIN YUN-CHU; Lu, Li-Chun; Wu, Shang-Ju; Kuo, Sung-Hsin; Hong, Ruey-Long; Huang, Tai-Chung; MING YAO |
| 臺大學術典藏 |
2022-01-10T09:11:05Z |
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang, Yu-Wen; Tsai, Cheng-Hong; Hou, Hsin-An; TIEN FENG-MING; LIU JIA-HAU; Chou, Wen-Chien; Ko, Bor-Sheng; Chen, Yu-Wen; Lin, Chien-Chin; Cheng, Chieh-Lung; Lo, Min-Yen; LIN YUN-CHU; Lu, Li-Chun; Wu, Shang-Ju; Kuo, Sung-Hsin; Hong, Ruey-Long; Huang, Tai-Chung; MING YAO |
| 臺大學術典藏 |
2021-12-16T02:12:55Z |
Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma
|
YANG SHIH-HUNG; Lu, Li-Chun; Kao, Hsiang-Fong; BANG-BIN CHEN; Kuo, Ting-Chun; Kuo, Sung-Hsin; Tien, Yu-Wen; Bai, Li-Yuan; Cheng, Ann-Lii; Yeh, Kun-Huei |
| 臺大學術典藏 |
2021-11-29T05:34:46Z |
Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma
|
Yang, Shih-Hung; Lu, Li-Chun; Kao, Hsiang-Fong; Chen, Bang-Bin; TING-CHUN KUO; Kuo, Sung-Hsin; Tien, Yu-Wen; Bai, Li-Yuan; Cheng, Ann-Lii; Yeh, Kun-Huei |
| 臺大學術典藏 |
2021-11-25T02:38:28Z |
Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance
|
Wang, Yulei; Lu, Li-Chun; Guan, Yinghui; MING-CHIH HO; Lu, Shan; Spahn, Jessica; Hsu, Chih-Hung |
| 臺大學術典藏 |
2021-11-24T07:22:42Z |
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang, Yu-Wen; Tsai, Xavier Cheng-Hong; Hou, Hsin-An; TIEN FENG-MING; LIU JIA-HAU; Chou, Wen-Chien; Ko, Bor-Sheng; Chen, Yu-Wen; CHIEN-CHIN LIN; Cheng, Chieh-Lung; Lo, Min-Yen; LIN YUN-CHU; Lu, Li-Chun; Wu, Shang-Ju; Kuo, Sung-Hsin; Hong, Ruey-Long; Huang, Tai-Chung; MING YAO |
| 臺大學術典藏 |
2021-11-21T23:19:44Z |
Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang, Yu Wen; Tsai, Xavier Cheng Hong; HSIN-AN HOU; Tien, Feng Ming; Liu, Jia Hau; WEN-CHIEN CHOU; BOR-SHENG KO; YU-WEN CHEN; CHIEN-CHIN LIN; Cheng, Chieh Lung; Lo, Min Yen; Lin, Yun Chu; Lu, Li Chun; SHANG-JU WU; SUNG-HSIN KUO; Hong, Ruey Long; TAI-CHUNG HUANG; MING YAO |
| 臺大學術典藏 |
2021-10-21T23:28:03Z |
Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites
|
Guo, Jhe Cyuan; Lin, Chen Yuan; Chia-Chi Lin; Huang, Ta Chen; Lien, Ming Yu; Lu, Li Chun; HUNG-YANG KUO; Chih-Hung Hsu |
| 臺大學術典藏 |
2021-10-21T23:27:09Z |
Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma
|
SHIH-HUNG YANG; Lu, Li Chun; HSIANG-FONG KAO; BANG-BIN CHEN; TING-CHUN KUO; SUNG-HSIN KUO; YU-WEN TIEN; Bai, Li Yuan; ANN-LII CHENG; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-09-14T23:18:53Z |
Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance
|
Wang, Yulei; Lu, Li Chun; Guan, Yinghui; MING-CHIH HO; Lu, Shan; Spahn, Jessica; CHIH-HUNG HSU |
| 臺大學術典藏 |
2021-09-09T08:45:43Z |
Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites
|
GUO, JHE-CYUAN; Lin, Chen-Yuan; Lin, Chia-Chi; Huang, Ta-Chen; Lien, Ming-Yu; Lu, Li-Chun; Kuo, Hung-Yang; Hsu, Chih-Hung |
| 臺大學術典藏 |
2020-04-09T09:34:35Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Cheng, Ann Lii;Hsu, Chih Hung;Lin, Zhong Zhe;Hsu, Chiun;Shen, Ying Chun;Lu, Li Chun;Shao, Yu Yun;Liu, Tsung Hao; Liu, Tsung Hao; Shao, Yu Yun; Lu, Li Chun; Shen, Ying Chun; Hsu, Chiun; Lin, Zhong Zhe; Hsu, Chih Hung; Cheng, Ann Lii |
| 臺大學術典藏 |
2019-09-09T00:55:32Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu, Li Chun;YU-YUN SHAO;Shen, Ying Chun;Hsu, Chiun;YI-PING HUNG;CHIH-HUNG HSU;Liu, Tsung Hao;ANN-LII CHENG;Guo, Jhe Cyuan;Yen, Chia Jui;Chang, Chun Jung;I-LUN SHIH;Chao, Yee; Chao, Yee; I-LUN SHIH; Chang, Chun Jung; Yen, Chia Jui; Guo, Jhe Cyuan; ANN-LII CHENG; Liu, Tsung Hao; CHIH-HUNG HSU; YI-PING HUNG; Hsu, Chiun; Shen, Ying Chun; YU-YUN SHAO; Lu, Li Chun |
| 臺大學術典藏 |
2019-03-01 |
Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment
|
Hsu, Chih Hung; Cheng, Ann Lii; Liu, Tsung Hao; Shao, Yu Yun; Fang, Chih Yeu; Shun, Chia Tung; Hsu, Chih Hung;Cheng, Ann Lii;Liu, Tsung Hao;Shao, Yu Yun;Fang, Chih Yeu;Shun, Chia Tung;Chang, Chun Jung;Lee, Yi Hsuan;Lu, Li Chun; Lu, Li Chun; Lee, Yi Hsuan; Chang, Chun Jung |
| 臺大學術典藏 |
2018-09-10T14:51:53Z |
beta-Catenin (CTNNB1) Mutations Are Not Associated with Prognosis in Advanced Hepatocellular Carcinoma
|
高祥豐;邵幼雲;鄭安理;徐志宏;呂理駿;謝明書;李宜軒; Lu, Li-Chun; MIN-SHU HSIEH; CHIH-HUNG HSU; Shao, Yu-Yun; Lee, Yi-Hsuan; HSIANG-FONG KAO; Yu-Yun Shao; Hsieh, Min-Shu; ANN-LII CHENG; Hsiao, Chi-Huang; Lin, Hsiao-Hui; Kao, Hsiang-Fong; Ma, Yu-Yi; Yen, Feng-Chu; Cheng, Ann-Lii; Hsu, Chih-Hung; Lu, Li-Chun;Shao, Yu-Yun;Lee, Yi-Hsuan;Hsieh, Min-Shu;Hsiao, Chi-Huang;Lin, Hsiao-Hui;Kao, Hsiang-Fong;Ma, Yu-Yi;Yen, Feng-Chu;Cheng, Ann-Lii;Hsu, Chih-Hung; Lu, Li-Chun and Shao, Yu-Yun and Lee, Yi-Hsuan and Hsieh, Min-Shu and Hsiao, Chi-Huang and Lin, Hsiao-Hui and Kao, Hsiang-Fong and Ma, Yu-Yi and Yen, Feng-Chu and Cheng, Ann-Lii and Hsu, Chih-Hung |
| 臺大學術典藏 |
2018-09-10T06:33:02Z |
Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan
|
Shao, Yu-Yun; Liu, CJ; PEI-JER CHEN; Lai, MY; DING-SHINN CHEN; Lee, Yi-Hsuan; Hsieh, Min-Shu; JIA-HORNG KAO; Chen, PJ; Kao, JH; Hsiao, Chi-Huang; Lin, Hsiao-Hui; Chen, DS.; Kao, Hsiang-Fong; Ma, Yu-Yi; Yen, Feng-Chu; Cheng, Ann-Lii; Hsu, Chih-Hung; 高祥豐; 邵幼雲; 鄭安理; 徐志宏; 呂理駿; 謝明書; 李宜軒; Hsu, CS; Hsu, C.-S.; Liu, C.-J.; Lai, M.-Y.; Chen, P.-J.; Kao, J.-H.; Chen, D.-S.; Lu, Li-Chun; CHUN-JEN LIU |
| 國立臺灣大學 |
2016 |
Inhibition of the Wnt/beta-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma
|
Lin, Hsiao-Hui; Feng, Wen-Chi; Lu, Li-Chun; Shao, Yu-Yun; Hsu, Chih-Hung; Cheng, Ann-Lii; 邵幼雲; 鄭安理; 徐志宏; 呂理駿 |
| 國立臺灣大學 |
2016 |
Tumor-associated neutrophils: an emerging player in the immune microenvironment of hepatocellular carcinoma
|
Lu, Li-Chun; Hsu, Chih-Hung; 徐志宏; 呂理駿 |
| 國立臺灣大學 |
2016 |
Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges
|
Lu, Li-Chun; Hsu, Chih-Hung; Hsu, Chiun; Cheng, Ann-Lii; 鄭安理; 徐志宏; 許駿; 呂理駿 |
| 國立臺灣大學 |
2015 |
Treatment Efficacy Differences of Sorafenib for Advanced Hepatocellular Carcinoma: A Meta-Analysis of Randomized Clinical Trials
|
Shao, Yu-Yun; Shau, Wen-Yi; Chan, Soa-Yu; Lu, Li-Chun; Hsu, Chih-Hung; Cheng, Ann-Lii; 邵幼雲; 鄭安理; 徐志宏; 呂理駿 |
| 國立臺灣大學 |
2014 |
beta-Catenin (CTNNB1) Mutations Are Not Associated with Prognosis in Advanced Hepatocellular Carcinoma
|
Lu, Li-Chun; Shao, Yu-Yun; Lee, Yi-Hsuan; Hsieh, Min-Shu; Hsiao, Chi-Huang; Lin, Hsiao-Hui; Kao, Hsiang-Fong; Ma, Yu-Yi; Yen, Feng-Chu; Cheng, Ann-Lii; Hsu, Chih-Hung; 高祥豐; 邵幼雲; 鄭安理; 徐志宏; 呂理駿; 謝明書; 李宜軒 |
| 國立臺灣大學 |
2014 |
Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy
|
Shao, Yu-Yun; Wu, Chih-Horng; Lu, Li-Chun; Chan, Soa-Yu; Ma, Yu-Yi; Yen, Feng-Chu; Hsu, Chih-Hung; Cheng, Ann-Lii; 邵幼雲; 吳志宏; 鄭安理; 徐志宏; 呂理駿 |
| 國立臺灣大學 |
2014 |
Clinical Characteristics of Advanced Hepatocellular Carcinoma Patients with Prolonged Survival in the Era of Anti-angiogenic Targeted-therapy
|
Lu, Li-Chun; Shao, Yu-Yun; Chan, Soa-Yu; Hsu, Chih-Hung; Cheng, Ann-Lii; 邵幼雲; 鄭安理; 徐志宏; 呂理駿 |
| 國立臺灣大學 |
2014 |
Recent Advances in the Prevention of Hepatocellular Carcinoma Recurrence
|
Lu, Li-Chun; Cheng, Ann-Lii; Poon, Ronnie T. P.; 鄭安理; 呂理駿 |
Showing items 6-30 of 38 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
|
